Ceftazidime/avibactam Combined with Colistin: a Novel Attempt to Treat Carbapenem-resistant Gram-negative Bacilli Infection

Overview

Journal BMC Infect Dis

Publisher Biomed Central

Specialty Infectious Diseases

Date 2023 Oct 20

PMID 37864200

Authors

Zihao Zheng

Ziqiang Shao

Lihai Lu

Siyu Tang

Kai Shi

Fangxiao Gong

Jingquan Liu

Affiliations

Soon will be listed here.

Abstract

Background: The rapid global emergence and spread of carbapenem-resistant Gram-negative bacilli (CR-GNB) is recognized as a major public health concern, and there are currently few effective treatments for CR-GNB infection. The aim of this study was to investigate the clinical characteristics and outcomes of patients with CR-GNB infections treated with ceftazidime/avibactam (CAZ/AVI) combined with colistin from October 2019 to February 2023 in China.

Methods: A total of 31 patients with CR-GNB infections were retrospectively identified using the electronic medical record system of Zhejiang Provincial People's Hospital.

Results: Thirty-one patients were treated with CAZ/AVI combined with colistin. Respiratory tract infections (87%) were most common. The common drug-resistant bacteria encompass Klebsiella pneumonia (54.8%), Acinetobacter baumannii (29.0%), and Pseudomonas aeruginosa (16.1%). The 30-day mortality rate was 29.0%, and the 7-day microbial clearance rate was 64.5%. The inflammatory marker CRP changes, but not PCT and WBC, were statistically significant on days 7 and 14 after combination therapy. There were seven patients developing acute renal injury (AKI) after combination therapy and treating with continuous renal replacement therapy (CRRT). Two patients developed diarrhea.

Conclusion: The combination of CAZ/AVI and colistin has potential efficacy in patients with CR-GNB infection, but more studies are needed to determine whether it can reduce 30-day mortality rates and increase 7-day microbial clearance. At the same time, the adverse reactions of combination therapy should not be ignored.

Citing Articles

Colistin Resistance Mechanism and Management Strategies of Colistin-Resistant Infections.

Islam M, Jung D, Shin W, Oh M Pathogens. 2025; 13(12.

PMID: 39770308 PMC: 11728550. DOI: 10.3390/pathogens13121049.

Navigating the Current Treatment Landscape of Metallo-β-Lactamase-Producing Gram-Negative Infections: What are the Limitations?.

Grabein B, Arhin F, Daikos G, Moore L, Balaji V, Baillon-Plot N Infect Dis Ther. 2024; 13(11):2423-2447.

PMID: 39352652 PMC: 11499561. DOI: 10.1007/s40121-024-01044-8.

References

Wagenlehner F, Sobel J, Newell P, Armstrong J, Huang X, Stone G . Ceftazidime-avibactam Versus Doripenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: RECAPTURE, a Phase 3 Randomized Trial Program. Clin Infect Dis. 2016; 63(6):754-762. PMC: 4996135. DOI: 10.1093/cid/ciw378. View

Band V, Hufnagel D, Jaggavarapu S, Sherman E, Wozniak J, Satola S . Antibiotic combinations that exploit heteroresistance to multiple drugs effectively control infection. Nat Microbiol. 2019; 4(10):1627-1635. PMC: 7205309. DOI: 10.1038/s41564-019-0480-z. View

Katip W, Oberdorfer P, Kasatpibal N . Effectiveness and Nephrotoxicity of Loading Dose Colistin-Meropenem versus Loading Dose Colistin-Imipenem in the Treatment of Carbapenem-Resistant Infection. Pharmaceutics. 2022; 14(6). PMC: 9228626. DOI: 10.3390/pharmaceutics14061266. View

Le Minh V, Nhu N, Phat V, Thompson C, Lan N, Thieu Nga T . In vitro activity of colistin in antimicrobial combination against carbapenem-resistant Acinetobacter baumannii isolated from patients with ventilator-associated pneumonia in Vietnam. J Med Microbiol. 2015; 64(10):1162-1169. PMC: 4755130. DOI: 10.1099/jmm.0.000137. View

Mataraci Kara E, Yilmaz M, Tosun A, Ozbek Celik B . Evaluation of the synergy of ceftazidime/avibactam in combination with colistin, doripenem, levofloxacin, tigecycline, and tobramycin against OXA-48 producing Enterobacterales. J Chemother. 2020; 32(4):171-178. DOI: 10.1080/1120009X.2020.1761172. View

Katip W, Oberdorfer P . Clinical Efficacy and Nephrotoxicity of Colistin Alone versus Colistin Plus Vancomycin in Critically Ill Patients Infected with Carbapenem-Resistant : A Propensity Score-Matched Analysis. Pharmaceutics. 2021; 13(2). PMC: 7912140. DOI: 10.3390/pharmaceutics13020162. View

Li J, Lovern M, Green M, Chiu J, Zhou D, Comisar C . Ceftazidime-Avibactam Population Pharmacokinetic Modeling and Pharmacodynamic Target Attainment Across Adult Indications and Patient Subgroups. Clin Transl Sci. 2018; 12(2):151-163. PMC: 6440567. DOI: 10.1111/cts.12585. View

Hao M, Yang Y, Guo Y, Wu S, Hu F, Qin X . Combination Regimens with Colistin Sulfate versus Colistin Sulfate Monotherapy in the Treatment of Infections Caused by Carbapenem-Resistant Gram-Negative Bacilli. Antibiotics (Basel). 2022; 11(10). PMC: 9598655. DOI: 10.3390/antibiotics11101440. View

Katip W, Rayanakorn A, Oberdorfer P, Taruangsri P, Nampuan T . Short versus long course of colistin treatment for carbapenem-resistant A. baumannii in critically ill patients: A propensity score matching study. J Infect Public Health. 2023; 16(8):1249-1255. DOI: 10.1016/j.jiph.2023.05.024. View

10.

Oweis A, Zeyad H, Alshelleh S, Alzoubi K . Acute Kidney Injury Among Patients with Multi-Drug Resistant Infection: A Study from Jordan. J Multidiscip Healthc. 2022; 15:2759-2766. PMC: 9733443. DOI: 10.2147/JMDH.S384386. View

11.

Capsoni N, Bellone P, Aliberti S, Sotgiu G, Pavanello D, Visintin B . Prevalence, risk factors and outcomes of patients coming from the community with sepsis due to multidrug resistant bacteria. Multidiscip Respir Med. 2019; 14:23. PMC: 6610920. DOI: 10.1186/s40248-019-0185-4. View

12.

Yahav D, Giske C, Gramatniece A, Abodakpi H, Tam V, Leibovici L . New β-Lactam-β-Lactamase Inhibitor Combinations. Clin Microbiol Rev. 2020; 34(1). PMC: 7667665. DOI: 10.1128/CMR.00115-20. View

13.

Frohlich C, Sorum V, Thomassen A, Johnsen P, Leiros H, Samuelsen O . OXA-48-Mediated Ceftazidime-Avibactam Resistance Is Associated with Evolutionary Trade-Offs. mSphere. 2019; 4(2). PMC: 6437269. DOI: 10.1128/mSphere.00024-19. View

14.

Li J, Nation R, Milne R, Turnidge J, Coulthard K . Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria. Int J Antimicrob Agents. 2004; 25(1):11-25. DOI: 10.1016/j.ijantimicag.2004.10.001. View

15.

Torres A, Zhong N, Pachl J, Timsit J, Kollef M, Chen Z . Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial. Lancet Infect Dis. 2017; 18(3):285-295. DOI: 10.1016/S1473-3099(17)30747-8. View

16.

Potter R, DSouza A, Dantas G . The rapid spread of carbapenem-resistant Enterobacteriaceae. Drug Resist Updat. 2016; 29:30-46. PMC: 5140036. DOI: 10.1016/j.drup.2016.09.002. View

17.

Wang F, Zhou Q, Yang X, Bai Y, Cui J . Evaluation of ceftazidime/avibactam alone and in combination with amikacin, colistin and tigecycline against Klebsiella pneumoniae carbapenemase-producing K. pneumoniae by in vitro time-kill experiment. PLoS One. 2021; 16(10):e0258426. PMC: 8516195. DOI: 10.1371/journal.pone.0258426. View

18.

Li J, Nation R, Turnidge J, Milne R, Coulthard K, Rayner C . Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis. 2006; 6(9):589-601. DOI: 10.1016/S1473-3099(06)70580-1. View

19.

Viderman D, Khamzina Y, Kaligozhin Z, Khudaibergenova M, Zhumadilov A, Crape B . An observational case study of hospital associated infections in a critical care unit in Astana, Kazakhstan. Antimicrob Resist Infect Control. 2018; 7:57. PMC: 5918921. DOI: 10.1186/s13756-018-0350-0. View

20.

Wolffers O, Faltys M, Thomann J, Jakob S, Marschall J, Merz T . An automated retrospective VAE-surveillance tool for future quality improvement studies. Sci Rep. 2021; 11(1):22264. PMC: 8593155. DOI: 10.1038/s41598-021-01402-3. View